Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cirrhosis

Cirrhosis

Subtypes of Cirrhosis

Primary biliary cholangitis 9 Liver Fibrosis 8 Decompensated liver cirrhosis 6 Fibrosis 5 End-stage liver disease 4 Compensated cirrhosis 3 Keloid 3 Acute decompensation of cirrhosis 1 Compensated MASH cirrhosis 1 Decompensated liver failure 1

64 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cirrhosis

82 trials tracked for Cirrhosis: 27 in phase 3 or 4 and 2 with published results. The most-cited published study has 46 citations.

82Trials tracked
27Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 12 Phase 3 15 Phase 2 22 Phase 1 3 Other / NA 30
  1. Phase 4 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Completed · 46 cited
  2. Phase 3 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Completed · 24 cited
  3. Phase 4 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed
  4. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  5. Phase 4 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant Completed
  6. Phase 4 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis Completed
Show 44 more trials
  1. Phase 4 Ramelteon for Treatment of Insomnia in Cirrhosis Completed
  2. Phase 4 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed
  3. Phase 4 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Completed
  4. Phase 4 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed
  5. Phase 4 Tolvaptan for Ascites in Cirrhotic Patients Completed
  6. Phase 4 Steroid Free Immunosuppression in Liver Transplantation Completed
  7. Phase 4 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed
  8. Phase 3 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  9. Phase 3 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study Completed
  10. Phase 3 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? Completed
  11. Phase 3 A Trial to Improve Quality of Life in People With Cirrhosis Completed
  12. Phase 3 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Completed
  13. Phase 3 Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) Completed
  14. Phase 3 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis Completed
  15. Phase 3 Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) Completed
  16. Phase 3 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema Completed
  17. Phase 3 PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) Completed
  18. Phase 3 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema Completed
  19. Phase 3 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg Completed
  20. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  21. Phase 3 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) Completed
  22. Phase 2 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Completed
  23. Phase 2 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients Completed
  24. Phase 2 FMT in Cirrhosis and Hepatic Encephalopathy Completed
  25. Phase 2 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation Completed
  26. Phase 2 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Completed
  27. Phase 2 A Study of IDN-6556 in Subjects With Liver Cirrhosis Completed
  28. Phase 2 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Completed
  29. Phase 2 VE303 for Treatment of Hepatic Encephalopathy (HE) Completed
  30. Phase 2 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Completed
  31. Phase 2 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Completed
  32. Phase 2 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Completed
  33. Phase 2 A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients Completed
  34. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  35. Phase 2 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C Completed
  36. Phase 2 Human Fetal Liver Cell Transplantation in Chronic Liver Failure Completed
  37. Phase 2 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study Completed
  38. Phase 2 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Completed
  39. Phase 2 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema Completed
  40. Phase 2 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Completed
  41. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  42. Phase 2 MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Completed
  43. Phase 2 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer Completed
  44. Phase 1 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis Completed

Showing the 50 most-cited and recently-updated of 82 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Exercise programs improve muscle mass and physical performance indicators in patients with liver cirrhosis
Rheumatology Meta-analysis
Exercise programs improve muscle mass and physical performance indicators in patients with liver cirrhosis Exercise improves muscle strength in cirrhosis patients
This meta-analysis of 16 studies involving 942 patients found that exercise interventions significantly improved 6-min walk distance, thigh …
Exercise boosts muscle mass and walking ability in people with cirrhosis and muscle loss, a new analysis finds.
Frontiers Jul 29, 2026
Single-cell RNA sequencing identifies post-capillary venules and ADAM12+ fibroblasts as potential keloid targets
Dermatology Meta-analysis
Single-cell RNA sequencing identifies post-capillary venules and ADAM12+ fibroblasts as potential keloid targets New research identifies specific cell types driving keloid scar growth
This meta-analysis of transcriptomic data uses single-cell RNA sequencing to identify cellular compositions in keloids across diverse ethnic…
Researchers identified specific blood vessel and skin cell types that may drive the growth of keloids across different ethnicities.
Frontiers Jul 18, 2026
Tryptophan metabolism pathways like IDO and TDO2 influence immune cell function in end-stage liver disease
Gastroenterology Sys. Review
Tryptophan metabolism pathways like IDO and TDO2 influence immune cell function in end-stage liver disease New research explores how liver enzymes impact transplant immunity
This systematic review examines the role of tryptophan metabolism, specifically the kynurenine pathway and AhR signaling, in immune toleranc…
Scientists are looking at how specific pathways in the body might help patients with end-stage liver disease accept transplants.
Frontiers Jul 16, 2026
Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis
Gastroenterology Meta-analysis
Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis Gut Microbiota Differences Linked to Primary Biliary Cholangitis
This meta-analysis of 1,057 participants found that patients with primary biliary cholangitis have significantly lower Shannon index values …
A large review of patient data shows that people with primary biliary cholangitis have significantly lower gut bacterial diversity than heal…
Frontiers Jun 10, 2026
Systematic review shows intralesional vitamin D reduces steroid risks for keloid patients
Rheumatology Meta-analysis
Systematic review shows intralesional vitamin D reduces steroid risks for keloid patients Triamcinolone works better for keloids, but vitamin D spares skin damage
A meta-analysis of four trials found intralesional triamcinolone acetonide superior for scar improvement versus vitamin D. However, vitamin …
Triamcinolone acetonide improves keloid scars more than vitamin D, yet vitamin D lowers risks of skin thinning and color changes.
Frontiers Jun 3, 2026
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Frontiers Jun 2, 2026
FIPS AUC 0.821 outperforms MELD scores for 90-day mortality prediction in TIPS for ascites
Gastroenterology Meta-analysis
FIPS AUC 0.821 outperforms MELD scores for 90-day mortality prediction in TIPS for ascites New score outperforms MELD for predicting death after TIPS for bleeding
This meta-analysis of 5,180 patients undergoing TIPS for ascites or gastroesophageal bleeding compared MELD-based scores and the FIPS index …
A new scoring system called FIPS may better predict 90-day death risk after TIPS for bleeding than older MELD scores.
Jun 1, 2026
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients
Gastroenterology RCT
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients Trained liver doctors provided care that matched specialists for patients with serious liver disease
A US trial found hepatologist-delivered palliative care noninferior to specialist care for improving quality of life in advanced liver disea…
Patients with advanced liver disease saw similar quality of life improvements when cared for by trained liver doctors versus specialists. Bo…
Jun 1, 2026
Endovascular interventions reduce rebleeding risk versus endoscopic cyanoacrylate injection in gastric variceal hemorrhage
Gastroenterology Meta-analysis
Endovascular interventions reduce rebleeding risk versus endoscopic cyanoacrylate injection in gastric variceal hemorrhage Endovascular procedures reduce rebleeding risk for cirrhosis patients compared to injection therapy
This individual patient data meta-analysis compares endovascular interventions with endoscopic cyanoacrylate injection for gastric variceal …
A meta-analysis of 1,240 patients found endovascular procedures significantly lower rebleeding rates than injection therapy, though they car…
Jun 1, 2026
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings
Gastroenterology Meta-analysis
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings Antimicrobial resistance is rising in cirrhosis patients worldwide
This systematic review and meta-analysis examines bacterial infections in 35,180 adult patients with cirrhosis globally. The analysis report…
A global analysis of 35,180 patients with cirrhosis shows rising antimicrobial resistance and varying mortality risks.
Jun 1, 2026
Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies
Drug Pipeline Meta-analysis
Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies Combination therapy improves biochemical markers in primary biliary cholangitis
An umbrella meta-analysis of meta-analyses involving 3,276 patients shows that adding fibrates to ursodeoxycholic acid significantly lowers …
Combining fibrates with ursodeoxycholic acid improves liver markers in primary biliary cholangitis patients, though survival data remain unc…
Frontiers May 25, 2026
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
Allergy & Immunology Sys. Review
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
Frontiers May 18, 2026

Questions about Cirrhosis

How common is depression among patients with liver cirrhosis?

Depression is very common in liver cirrhosis, affecting about 37% of patients globally, yet it often goes undiagnosed.

Full answer →
Can the Patient Buddy App help reduce hospital readmissions for my cirrhosis?

Yes, the Patient Buddy App reduced avoidable hospital readmissions in cirrhosis patients by about half in a clinical trial, but discuss with your doctor if it's right for you.

Full answer →